SCHEMBL1612079

SCHEMBL1612079

CC(=O)Nc1cccc2c1C(=O)CC2

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOA P21397 1/20 0.51
ALDH1A1 P00352 5/20 0.50
HPGD P15428 2/20 0.50
KDM4E B2RXH2 2/20 0.50
GAA P10253 1/20 0.50
HSD17B10 Q99714 1/20 0.50
NPC1 O15118 2/20 0.49
RAB9A P51151 2/20 0.49
CASP3 P42574 1/20 0.48
AHR P35869 1/20 0.43
CCNE2 O96020 3/20 0.42
CCNE1 P24864 3/20 0.42
CDK2 P24941 3/20 0.42
DDB1 Q16531 1/20 0.41
CRBN Q96SW2 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.40
POLB P06746 1/20 0.40
CYP2C19 P33261 1/20 0.40
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4877329 0.90 MAOA (0.49) MAOAALDH1A1HPGDKDM4EGAA
SCHEMBL1337358 0.90 BAZ2B (0.49) MAOAALDH1A1HPGDKDM4EGAA
SCHEMBL21393160 0.80 TGM2 (0.41) ALDH1A1HSD17B10KMT2A
SCHEMBL7653367 0.79 MAOA (0.48) MAOAALDH1A1HPGDKDM4EGAA
SCHEMBL25445162 0.79 MAPT (0.46) ALDH1A1HPGDKDM4EHSD17B10RAB9A
SCHEMBL2297983 0.79 NPC1 (0.41) MAOAALDH1A1HPGDKDM4EGAA
SCHEMBL21098726 0.76 NPC1 (0.46) MAOAALDH1A1HPGDKDM4EGAA
SCHEMBL8789258 0.75 BAZ2B (0.37) MAOAALDH1A1HPGDKDM4EGAA
SCHEMBL7662566 0.75 MAOA (0.47) MAOAALDH1A1HPGDKDM4EGAA
SCHEMBL7653374 0.75 KDM4E (0.50) MAOAALDH1A1HPGDKDM4EGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10233146-B2 Acetylenic cyanoenones as therapeutics for inflammation and carcinogenesis THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) 2019-03-19 US disclosed
US-20180193315-A1 SPIROCYCLIC HAT INHIBITORS AND METHODS FOR THEIR USE ABBVIE INC (US) 2018-07-12 US disclosed
US-20180134654-A1 ACETYLENIC CYANOENONES AS THERAPEUTICS FOR INFLAMMATION AND CARCINOGENESIS THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) 2018-05-17 US disclosed
US-20180071262-A1 SPIROCYCLIC HAT INHIBITORS AND METHODS FOR THEIR USE ABBVIE INC. (US) 2018-03-15 US disclosed
US-20160235716-A1 SPIROCYCLIC HAT INHIBITORS AND METHODS FOR THEIR USE ABBVIE INC. (US) 2016-08-18 US disclosed
WO-2016044770-A1 SPIROCYCLIC HAT INHIBITORS AND METHODS FOR THEIR USE ABBVIE INC. (US) 2016-03-24 WO disclosed
EP-1781640-B1 2,4-DI(AMINOPHENYL)PYRIMIDINE DERIVATIVES AS PLK INHIBITORS BOEHRINGER INGELHEIM INT (DE) 2015-01-07 EP disclosed
US-20110086842-A1 Pyrimidines as PLK inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-04-14 US disclosed
US-20090163465-A1 Pyrimidines as PLK inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-06-25 US disclosed
US-20090149438-A1 Pyrimidines as PLK inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-06-11 US disclosed
US-7521457-B2 Pyrimidines as PLK inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-04-21 US disclosed
CN-101044137-A 2,4-di(aminophenyl)pyrimidine derivatives as plk inhibitors BOEHRINGER INGELHEIM INT (DE) 2007-09-26 CN disclosed
US-20060148800-A1 Pyrimidines as PLK inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2006-07-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160235716-A1 SPIROCYCLIC HAT INHIBITORS AND METHODS FOR THEIR USE KAT2B, HDAC1, HDAC9 MAOA 176/4885ALDH1A1 601/4885HPGD 1366/4885
US-20180134654-A1 ACETYLENIC CYANOENONES AS THERAPEUTICS FOR INFLAMMATION AND CARCINOGENESIS ACOX3, ACOT7, ACOX1 MAOA 4113/4885ALDH1A1 1969/4885HPGD 659/4885
US-20090163465-A1 Pyrimidines as PLK inhibitors PLK2, PLK3, TYMP MAOA 2429/4885ALDH1A1 971/4885HPGD 3639/4885
US-20110086842-A1 Pyrimidines as PLK inhibitors PLK2, PLK3, TYMP MAOA 2429/4885ALDH1A1 971/4885HPGD 3639/4885
US-20090149438-A1 Pyrimidines as PLK inhibitors PLK2, PLK3, TYMP MAOA 2429/4885ALDH1A1 971/4885HPGD 3639/4885
US-20180193315-A1 SPIROCYCLIC HAT INHIBITORS AND METHODS FOR THEIR USE KAT2B, HDAC1, KAT2A MAOA 175/4885ALDH1A1 482/4885HPGD 1392/4885
US-10233146-B2 Acetylenic cyanoenones as therapeutics for inflammation and carcinogenesis ACOX3, ACOT7, ACOX1 MAOA 4114/4885ALDH1A1 1982/4885HPGD 667/4885
US-20180071262-A1 SPIROCYCLIC HAT INHIBITORS AND METHODS FOR THEIR USE KAT2B, HDAC1, HDAC9 MAOA 176/4885ALDH1A1 601/4885HPGD 1366/4885
US-20060148800-A1 Pyrimidines as PLK inhibitors PLK2, PLK3, TYMP MAOA 2429/4885ALDH1A1 971/4885HPGD 3639/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.